Pancreatic Cancer Research

ResearcherTokai UniversityActive in the last 2 years

Yohei Masugi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6952-4043; OpenAlex author ID A5056642819, A5124027249. Sources: OpenAlex.

Their work

Papers
36 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
123
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 5 papers · 2021: 2 papers · 2022: 5 papers · 2023: 2 papers · 2024: 3 papers · 2025: 6 papers · 2026: 3 papers

Papers 36

  1. Preoperative CD44v6-positive extracellular vesicles as a prognostic biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-026-02343-2↗
  2. Blocking L-carnitine synthesis by meldonium prolongs the survival in mice with pancreatic cancer. Co-author DOI 10.1016/j.isci.2026.117071↗
  3. Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. Co-author DOI 10.1038/s41416-025-03308-7↗
  4. Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.05.006↗
  5. Relationship of Intrapancreatic Fat Deposition With Pancreatic Cancer Differs According to Carcinoma Types. Co-author DOI 10.1053/j.gastro.2025.04.032↗
  6. Clinical Impact of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Single-Center Retrospective Study. Co-author DOI 10.1245/s10434-024-16851-z↗
  7. Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens. Co-author DOI 10.1245/s10434-025-17289-7↗
  8. ASO Author Reflections: Blood Group as a Guide for Adjuvant Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17381-y↗
  9. Pancreatic Cancer Mimicking Relapse of Autoimmune Pancreatitis: Case Reports. Co-author DOI 10.70352/scrj.cr.25-0076↗
  10. Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-024-72569-8↗
  11. Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline-resectable pancreatic cancer: a long-term follow-up study. Co-author DOI 10.1186/s12957-024-03609-w↗
  12. Next‑generation sequencing to identify genetic mutations in pancreatic cancer using intraoperative peritoneal washing fluid. Co-author DOI 10.3892/ol.2024.14272↗
  13. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. Co-author DOI 10.1002/cjp2.323↗
  14. Long-term survival after surgical resection for bone metastasis from pancreatic cancer: A case report. Co-author DOI 10.1097/md.0000000000035856↗
  15. Midazolam exhibits antitumour and anti-inflammatory effects in a mouse model of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bja.2021.12.042↗
  16. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. First author DOI 10.1111/cas.15398↗
  17. Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen-Response. Co-author DOI 10.1158/1078-0432.ccr-21-3693↗
  18. Increased alpha cell to beta cell ratio in patients with pancreatic cancer. Co-author DOI 10.1507/endocrj.ej22-0170↗
  19. The Desmoplastic Stroma of Pancreatic Cancer: Multilayered Levels of Heterogeneity, Clinical Significance, and Therapeutic Opportunities. Co-author DOI 10.3390/cancers14133293↗
  20. Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen. First author DOI 10.1158/1078-0432.ccr-20-2298↗
  21. Peritoneal dissemination of pancreatic cancer caused by endoscopic ultrasound-guided fine needle aspiration: A case report and literature review. Co-author DOI 10.3748/wjg.v27.i3.294↗
  22. Usefulness of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant thera… Co-author DOI 10.1002/cam4.3044↗
  23. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer. Co-author DOI 10.1111/cas.14425↗
  24. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-19-1315↗
  25. Discovery of Pancreatic Ductal Adenocarcinoma-Related Aberrant Glycosylations: A Multilateral Approach of Lectin Microarray-Based Tissue Glycomic Profiling Wit… Co-author DOI 10.3389/fonc.2020.00338↗
  26. O-Glycan-Altered Extracellular Vesicles: A Specific Serum Marker Elevated in Pancreatic Cancer. Co-author DOI 10.3390/cancers12092469↗
  27. Characterization of spatial distribution of tumor-infiltrating CD8+ T cells refines their prognostic utility for pancreatic cancer survival. Co-author DOI 10.1038/s41379-019-0291-z↗
  28. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline rese… Co-author DOI 10.1186/s12957-019-1687-4↗
  29. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  30. Mesenchymal-epithelial transition of pancreatic cancer cells at perineural invasion sites is induced by Schwann cells. Co-author DOI 10.1111/pin.12641↗
  31. Two cases of pancreatic ductal adenocarcinoma with intrapancreatic metastasis. Co-author DOI 10.3748/wjg.v22.i41.9222↗
  32. Upregulation of integrin β4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/labinvest.2014.166↗
  33. Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer. Co-author DOI 10.2302/kjm.2014-0014-cr↗
  34. Presence of primary cilia in cancer cells correlates with prognosis of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.humpath.2013.11.017↗
  35. Upregulated SMAD3 promotes epithelial-mesenchymal transition and predicts poor prognosis in pancreatic ductal adenocarcinoma. First author DOI 10.1038/labinvest.2014.53↗
  36. Mesenchymal stem cells regulate epithelial-mesenchymal transition and tumor progression of pancreatic cancer cells. Co-author DOI 10.1111/cas.12059↗

Closest collaborators

The 25 strongest of 123 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minoru Kitago · 23 shared papers, 2014–2026 · strength 3.00
  2. Shutaro Hori · 13 shared papers, 2019–2026 · strength 2.02
  3. Yuta Abe · 14 shared papers, 2015–2026 · strength 1.99
  4. Yutaka Nakano · 11 shared papers, 2019–2026 · strength 1.69
  5. Yuko Kitagawa · 16 shared papers, 2013–2026 · strength 1.60
  6. Michiie Sakamoto · 15 shared papers, 2013–2023 · strength 1.30
  7. Masayuki Tanaka · 7 shared papers, 2021–2025 · strength 1.29
  8. Tsuyoshi Hamada · 7 shared papers, 2020–2026 · strength 1.27
  9. Gaku Shimane · 6 shared papers, 2023–2026 · strength 1.18
  10. Mitsuhiro Fujishiro · 6 shared papers, 2022–2026 · strength 1.07
  11. Manabu Takamatsu · 5 shared papers, 2022–2026 · strength 0.99
  12. Sho Uemura · 5 shared papers, 2022–2026 · strength 0.89
  13. Yousuke Nakai · 5 shared papers, 2022–2026 · strength 0.83
  14. Ken Yamazaki · 7 shared papers, 2014–2022 · strength 0.66
  15. Yuko Kitagawa · 3 shared papers, 2024–2025 · strength 0.65
  16. Yosuke Uematsu · 3 shared papers, 2025–2026 · strength 0.65
  17. Yosuke Inoue · 4 shared papers, 2022–2026 · strength 0.63
  18. Kiyoshi Hasegawa · 4 shared papers, 2022–2026 · strength 0.63
  19. Tsuyoshi Takeda · 4 shared papers, 2022–2026 · strength 0.63
  20. Tatsunori Suzuki · 4 shared papers, 2022–2026 · strength 0.63
  21. Yu Takahashi · 4 shared papers, 2022–2026 · strength 0.63
  22. Naoki Sasahira · 4 shared papers, 2022–2026 · strength 0.63
  23. Yutaka Endo · 5 shared papers, 2019–2024 · strength 0.54
  24. Yoko Fujii‐Nishimura · 5 shared papers, 2015–2021 · strength 0.39
  25. Makoto Sano · 2 shared papers, 2022–2026 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.